Antibody data
- Antibody Data
- Antigen structure
- References [20]
- Comments [0]
- Validations
- Flow cytometry [1]
- Other assay [6]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MHCD1428 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD14 Monoclonal Antibody (TuK4), Pacific Blue™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Our Pacific Blue™ dye is optimally excited by the violet laser and conjugates of this dye are strongly fluorescent even at neutral pH. Pacific Blue™ and Pacific Orange™ dye conjugates can be simultaneously excited at 405 nm and emit at 455 nm and 551 nm, respectively, facilitating two-color analysis.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- TuK4
- Vial size
- 500 µL
- Storage
- 4° C, store in dark
Submitted references IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia.
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine.
GAD-alum immunotherapy in type 1 diabetes expands bifunctional Th1/Th2 autoreactive CD4 T cells.
Over-expression of PD-1 Does Not Predict Leukemic Relapse after Allogeneic Stem Cell Transplantation.
Principles Governing Establishment versus Collapse of HIV-1 Cellular Spread.
Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia.
Ten weeks of high-intensity interval walk training is associated with reduced disease activity and improved innate immune function in older adults with rheumatoid arthritis: a pilot study.
Barcoding of Macaque Hematopoietic Stem and Progenitor Cells: A Robust Platform to Assess Vector Genotoxicity.
T cell receptor β-chains display abnormal shortening and repertoire sharing in type 1 diabetes.
Effect of Antiretroviral Therapy on the Memory and Activation Profiles of B Cells in HIV-Infected African Women.
Immunization with Ty21a live oral typhoid vaccine elicits crossreactive multifunctional CD8+ T-cell responses against Salmonella enterica serovar Typhi, S. Paratyphi A, and S. Paratyphi B in humans.
Myocardial ischemia and reperfusion leads to transient CD8 immune deficiency and accelerated immunosenescence in CMV-seropositive patients.
Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy.
Atorvastatin induces T cell proliferation by a telomerase reverse transcriptase (TERT) mediated mechanism.
Unexpected heterogeneity of multifunctional T cells in response to superantigen stimulation in humans.
Quantitative and qualitative differences in the T cell response to HIV in uninfected Ugandans exposed or unexposed to HIV-infected partners.
Heterogeneity of multifunctional IL-17A producing S. Typhi-specific CD8+ T cells in volunteers following Ty21a typhoid immunization.
Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91(phox) expression and the PARP-1/PAR pathway of apoptosis.
A novel method for autophagy detection in primary cells: impaired levels of macroautophagy in immunosenescent T cells.
Anti-CD8 antibodies can trigger CD8+ T cell effector function in the absence of TCR engagement and improve peptide-MHCI tetramer staining.
Huuhtanen J, Ilander M, Yadav B, Dufva OM, Lähteenmäki H, Kasanen T, Klievink J, Olsson-Strömberg U, Stentoft J, Richter J, Koskenvesa P, Höglund M, Söderlund S, Dreimane A, Porkka K, Gedde-Dahl T, Gjertsen BT, Stenke L, Myhr-Eriksson K, Markevärn B, Lübking A, Dimitrijevic A, Udby L, Bjerrum OW, Hjorth-Hansen H, Mustjoki S
The Journal of clinical investigation 2022 Sep 1;132(17)
The Journal of clinical investigation 2022 Sep 1;132(17)
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine.
Rahmani NE, Ramachandra N, Sahu S, Gitego N, Lopez A, Pradhan K, Bhagat TD, Gordon-Mitchell S, Pena BR, Kazemi M, Rao K, Giricz O, Maqbool SB, Olea R, Zhao Y, Zhang J, Dolatshad H, Tittrea V, Tatwavedi D, Singh S, Lee J, Sun T, Steidl U, Shastri A, Inoue D, Abdel-Wahab O, Pellagatti A, Gavathiotis E, Boultwood J, Verma A
Blood cancer journal 2021 Sep 21;11(9):157
Blood cancer journal 2021 Sep 21;11(9):157
GAD-alum immunotherapy in type 1 diabetes expands bifunctional Th1/Th2 autoreactive CD4 T cells.
Arif S, Gomez-Tourino I, Kamra Y, Pujol-Autonell I, Hanton E, Tree T, Melandri D, Hull C, Wherrett DK, Beam C, Roep BO, Lorenc A, Peakman M
Diabetologia 2020 Jun;63(6):1186-1198
Diabetologia 2020 Jun;63(6):1186-1198
Over-expression of PD-1 Does Not Predict Leukemic Relapse after Allogeneic Stem Cell Transplantation.
Jain P, Tian X, Cordes S, Chen J, Cantilena CR, Bradley C, Panjwani R, Chinian F, Keyvanfar K, Battiwalla M, Muranski P, Barrett AJ, Ito S
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019 Feb;25(2):216-222
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019 Feb;25(2):216-222
Principles Governing Establishment versus Collapse of HIV-1 Cellular Spread.
Hataye JM, Casazza JP, Best K, Liang CJ, Immonen TT, Ambrozak DR, Darko S, Henry AR, Laboune F, Maldarelli F, Douek DC, Hengartner NW, Yamamoto T, Keele BF, Perelson AS, Koup RA
Cell host & microbe 2019 Dec 11;26(6):748-763.e20
Cell host & microbe 2019 Dec 11;26(6):748-763.e20
Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia.
Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, Aljanahi AA, Schreeder D, Klichinsky M, Shestova O, Kozlowski MS, Cummins KD, Shan X, Shestov M, Bagg A, Morrissette JJD, Sekhri P, Lazzarotto CR, Calvo KR, Kuhns DB, Donahue RE, Behbehani GK, Tsai SQ, Dunbar CE, Gill S
Cell 2018 May 31;173(6):1439-1453.e19
Cell 2018 May 31;173(6):1439-1453.e19
Ten weeks of high-intensity interval walk training is associated with reduced disease activity and improved innate immune function in older adults with rheumatoid arthritis: a pilot study.
Bartlett DB, Willis LH, Slentz CA, Hoselton A, Kelly L, Huebner JL, Kraus VB, Moss J, Muehlbauer MJ, Spielmann G, Kraus WE, Lord JM, Huffman KM
Arthritis research & therapy 2018 Jun 14;20(1):127
Arthritis research & therapy 2018 Jun 14;20(1):127
Barcoding of Macaque Hematopoietic Stem and Progenitor Cells: A Robust Platform to Assess Vector Genotoxicity.
Yabe IM, Truitt LL, Espinoza DA, Wu C, Koelle S, Panch S, Corat MAF, Winkler T, Yu KR, Hong SG, Bonifacino A, Krouse A, Metzger M, Donahue RE, Dunbar CE
Molecular therapy. Methods & clinical development 2018 Dec 14;11:143-154
Molecular therapy. Methods & clinical development 2018 Dec 14;11:143-154
T cell receptor β-chains display abnormal shortening and repertoire sharing in type 1 diabetes.
Gomez-Tourino I, Kamra Y, Baptista R, Lorenc A, Peakman M
Nature communications 2017 Nov 27;8(1):1792
Nature communications 2017 Nov 27;8(1):1792
Effect of Antiretroviral Therapy on the Memory and Activation Profiles of B Cells in HIV-Infected African Women.
Tanko RF, Soares AP, Müller TL, Garrett NJ, Samsunder N, Abdool Karim Q, Abdool Karim SS, Riou C, Burgers WA
Journal of immunology (Baltimore, Md. : 1950) 2017 Feb 1;198(3):1220-1228
Journal of immunology (Baltimore, Md. : 1950) 2017 Feb 1;198(3):1220-1228
Immunization with Ty21a live oral typhoid vaccine elicits crossreactive multifunctional CD8+ T-cell responses against Salmonella enterica serovar Typhi, S. Paratyphi A, and S. Paratyphi B in humans.
Wahid R, Fresnay S, Levine MM, Sztein MB
Mucosal immunology 2015 Nov;8(6):1349-59
Mucosal immunology 2015 Nov;8(6):1349-59
Myocardial ischemia and reperfusion leads to transient CD8 immune deficiency and accelerated immunosenescence in CMV-seropositive patients.
Hoffmann J, Shmeleva EV, Boag SE, Fiser K, Bagnall A, Murali S, Dimmick I, Pircher H, Martin-Ruiz C, Egred M, Keavney B, von Zglinicki T, Das R, Todryk S, Spyridopoulos I
Circulation research 2015 Jan 2;116(1):87-98
Circulation research 2015 Jan 2;116(1):87-98
Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy.
Ilander M, Kreutzman A, Rohon P, Melo T, Faber E, Porkka K, Vakkila J, Mustjoki S
PloS one 2014;9(1):e87794
PloS one 2014;9(1):e87794
Atorvastatin induces T cell proliferation by a telomerase reverse transcriptase (TERT) mediated mechanism.
Bennaceur K, Atwill M, Al Zhrany N, Hoffmann J, Keavney B, Breault D, Richardson G, von Zglinicki T, Saretzki G, Spyridopoulos I
Atherosclerosis 2014 Oct;236(2):312-20
Atherosclerosis 2014 Oct;236(2):312-20
Unexpected heterogeneity of multifunctional T cells in response to superantigen stimulation in humans.
McArthur MA, Sztein MB
Clinical immunology (Orlando, Fla.) 2013 Feb;146(2):140-52
Clinical immunology (Orlando, Fla.) 2013 Feb;146(2):140-52
Quantitative and qualitative differences in the T cell response to HIV in uninfected Ugandans exposed or unexposed to HIV-infected partners.
Pala P, Serwanga J, Watera C, Ritchie AJ, Moodie Z, Wang M, Goonetilleke N, Birabwa E, Hughes P, Senkaali D, Nakiboneka R, Grosskurth H, Haynes B, McMichael A, Kaleebu P, Center for HIV/AIDS Vaccine Immunology
Journal of virology 2013 Aug;87(16):9053-63
Journal of virology 2013 Aug;87(16):9053-63
Heterogeneity of multifunctional IL-17A producing S. Typhi-specific CD8+ T cells in volunteers following Ty21a typhoid immunization.
McArthur MA, Sztein MB
PloS one 2012;7(6):e38408
PloS one 2012;7(6):e38408
Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91(phox) expression and the PARP-1/PAR pathway of apoptosis.
Aurelius J, Thorén FB, Akhiani AA, Brune M, Palmqvist L, Hansson M, Hellstrand K, Martner A
Blood 2012 Jun 14;119(24):5832-7
Blood 2012 Jun 14;119(24):5832-7
A novel method for autophagy detection in primary cells: impaired levels of macroautophagy in immunosenescent T cells.
Phadwal K, Alegre-Abarrategui J, Watson AS, Pike L, Anbalagan S, Hammond EM, Wade-Martins R, McMichael A, Klenerman P, Simon AK
Autophagy 2012 Apr;8(4):677-89
Autophagy 2012 Apr;8(4):677-89
Anti-CD8 antibodies can trigger CD8+ T cell effector function in the absence of TCR engagement and improve peptide-MHCI tetramer staining.
Clement M, Ladell K, Ekeruche-Makinde J, Miles JJ, Edwards ES, Dolton G, Williams T, Schauenburg AJ, Cole DK, Lauder SN, Gallimore AM, Godkin AJ, Burrows SR, Price DA, Sewell AK, Wooldridge L
Journal of immunology (Baltimore, Md. : 1950) 2011 Jul 15;187(2):654-63
Journal of immunology (Baltimore, Md. : 1950) 2011 Jul 15;187(2):654-63
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Human peripheral blood monocytes stained using Pacific Blue Pacific Blue-H fluorochrome conjugates of anti-human CD14 monoclonal antibody (clone TuK4). The negative control profiles represent unstained cells.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 6 GAD-specific CD4 T cells induced by GAD-alum immunisation are bifunctional. ( a ) Representative GAD-specific CD4 T cell clone stimulated with diluent DMSO or ( b ) PMA/ionomycin for 3 h and stained for intracellular expression of IL-13 and IFN-gamma shows the clone's bifunctional potential. ( c ) GAD peptide-specific clone exhibits a bifunctionality when stimulated with cognate GAD65 555-567 peptide in vitro and analysed by dual-cytokine FluoroSpot. The control condition is stimulation with DMSO (the peptide diluent). The Th1/Th2 phenotype (IFN-gamma + /IL-13 + ) is shown in yellow. IFN-gamma responses are green and IL-13 are red (representative data from six clones). ( d ) Expression of cytokine and transcription factor mRNA by single sorted clone/line cells detected by PCR shows that a majority of GAD-alum induced bifunctional CD4 T cells co-express Th1 and Th2 differentiation markers TBX21 (encoding T-bet), IFNG and GATA3 as well as IL4 and/or IL13
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 1 CRISPR/Cas9-mediated correction of the ASXL1 mutation leads to increased myeloid differentiation. A The ASXL1 gene is made up of 12 exons with the ASXL1 G710X mutation in KBM5 cells located in exon 12. RNA-sequencing demonstrates CRISPR/Cas9-mediated correction of the ASXL1 G710X mutation in the leukemic KBM5 cell line. For the ASXL1 mutant cells, the red bar demonstrates the presence of the ASXL1 mutation at amino acid location 710, exon 12, chromosome 20. For the corrected cells, the red bar is absent at amino acid location 710, exon 12, chromosome 20, demonstrating correction of the ASXL1 mutation. In addition, the different colored bars in the corrected trace demonstrate silent nucleotide changes that were introduced to avoid undesired Cas9 activity in the mutation-corrected cells. B RNA-sequencing demonstrates that correction of the ASXL1 G710X mutation in the KBM5 cells by CRISPR/Cas9 gene-editing results in decreased expression of the HOXA9 gene. Increased expression of ITGAM/CD11b is demonstrated in the corrected isogenic cell line, suggesting increased myeloid differentiation. C Flow cytometry demonstrates increased expression of three myeloid surface markers, CD11b, CD14, and CD15, in the corrected cell line compared to the ASXL1 mutant cells, demonstrating increased myeloid differentiation with correction of the ASXL1 G710X mutation. Representative plots are shown. D Representative images of Giemsa stained ASXL1 mutant cells and those with homozygous correct
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 5 Azacytidine leads to increased differentiation in ASXL1 mutant cells. A Due to the increased methylation in the ASXL1 mutant cells, we treated the isogenic KBM5 cells with the DNMT inhibitor 5-azacytidine. Proliferation assays of the ASXL1 mutant cells and homozygous corrected cells treated with 5-Azacytidine revealed significantly decreased cell viability of the ASXL1 mutant cells, particularly when treated with 1 muM at 72 and 96 h. B Flow cytometric analysis of the isogenic KBM5 cells treated with 1 muM 5-Azacytidine for 96 h demonstrated increased differentiation with increased expression of CD11b and CD14 in the treated vs. untreated ASXL1 mutant cells. Furthermore, there is increased expression of CD11b and CD14 in the treated ASXL1 mutant cells compared to the untreated homozygous corrected cells. C Representative images of Giemsa stained untreated and 5-Azacytidine treated ASXL1 mutant cells and untreated and 5-Azacytidine treated homozygous corrected cells. Red arrows identify cells with decreased nucleus to cytoplasm ratio and condensed nuclei, consistent with myeloid maturation/differentiation. D Proliferation assays of the ASXL1 mutant and homozygous corrected cells treated with the combination of Venetoclax and 5-Azacytidine revealed significantly decreased cell viability of the ASXL1 mutant cells.